LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

LLY

984.76

+0.73%↑

JNJ

241.59

-0.56%↓

ABBV

219.68

-2.45%↓

NVS

153.09

-0.73%↓

AZN

190.11

-0.92%↓

Kodu・Aktsiate loetelu・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Suletud

SektorTervishoid

27.55 -0.33

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

27.11

Max

27.74

Põhinäitajad
By Trading Economics
Sissetulek	-28M 22M
Müük	4.3M 244M
P/E Sektori keskmine	10.542 61.417
Aktsiakasum	1.08
Kasumimarginaal	9.224
Töötajad	293
EBITDA	-22M 52M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+48.43% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2026

Turustatistika
By TradingEconomics
Turukapital	105M 1.7B
Eelmine avamishind	27.88
Eelmine sulgemishind	27.55

Uudiste sentiment

By Acuity

67%

33%

313 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

29.8 / N/A Toetus ja vastupanu

Harmony Biosciences Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. märts 2026, 19:08 UTC

Uudisväärsed sündmused

TotalEnergies Shutting Production in Qatar, Iraq Amid Fighting in Middle East

13. märts 2026, 18:48 UTC

Tulu

Suurimad hinnamuutused turgudel

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

13. märts 2026, 17:10 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

13. märts 2026, 17:10 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: Central Bank Decisions -2-

13. märts 2026, 16:47 UTC

Uudisväärsed sündmused

The Week in Oil: Hormuz Crisis Pushes Brent Above $100

13. märts 2026, 22:27 UTC

Market Talk

Uudisväärsed sündmused

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13. märts 2026, 22:13 UTC

Market Talk

Uudisväärsed sündmused

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13. märts 2026, 22:04 UTC

Market Talk

Uudisväärsed sündmused

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13. märts 2026, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 20:02 UTC

Market Talk

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13. märts 2026, 19:50 UTC

Market Talk

Uudisväärsed sündmused

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13. märts 2026, 19:35 UTC

Uudisväärsed sündmused

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

13. märts 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower -- Market Talk

13. märts 2026, 18:49 UTC

Uudisväärsed sündmused

The Iran War Could Upend AI. Here's How. -- Barrons.com

13. märts 2026, 18:24 UTC

Uudisväärsed sündmused

Impact of Middle East Conflict on TotalEnergies Activities

13. märts 2026, 18:00 UTC

Uudisväärsed sündmused

Is War Good For the Economy? -- WSJ

13. märts 2026, 17:23 UTC

Market Talk

U.S. Oil Rig Count Rises by 1 to 412 -- Market Talk

13. märts 2026, 16:46 UTC

Market Talk

Uudisväärsed sündmused

European Indexes End Week Lower as Oil Takes Driving Seat -- Market Talk

13. märts 2026, 16:38 UTC

Uudisväärsed sündmused

Higher Oil Prices Could Bring a Global Economic Shock. This Is the Number to Watch. -- Barrons.com

13. märts 2026, 16:34 UTC

Omandamised, ülevõtmised, äriostud

EQT Says It Received Around CHF21 Bln in Total From Galderma Share Sales

13. märts 2026, 16:33 UTC

Omandamised, ülevõtmised, äriostud

EQT Receives Proceeds of Around CHF1.3B From Sell-Down

13. märts 2026, 16:32 UTC

Omandamised, ülevõtmised, äriostud

EQT Completes Exit From Galderma

13. märts 2026, 16:20 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

13. märts 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. märts 2026, 16:15 UTC

Uudisväärsed sündmused

Why Exxon and Energy Stocks Finally Started to Rise This Week as the Iran War Escalated -- Barrons.com

13. märts 2026, 16:11 UTC

Market Talk

Carney Tries to Put Dismal Canada Jobs Data in Context -- Market Talk

13. märts 2026, 16:00 UTC

Uudisväärsed sündmused

Here's Where the U.S. Economy Is Most Vulnerable to Iran War -- WSJ

13. märts 2026, 15:48 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Turn Higher as Supply Worries Remain -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Harmony Biosciences Holdings Inc Prognoos

Hinnasiht

By TipRanks

48.43% tõus

12 kuu keskmine prognoos

Keskmine 41.25 USD 48.43%

Kõrge 62 USD

Madal 25 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Harmony Biosciences Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Harmony Biosciences Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

29.8 / N/AToetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

313 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.